35019-78-4

Upstream product

• 64-17-5 ethanol 
• 7206-70-4 4-amino-5-chloro-2-methoxybenzoic acid 

Downstream Products

• 1616458-56-0 ethyl 4-{[4-(2-{[(1-azabicyclo[2.2.2]oct-4-yloxy)carbonyl]amino}biphenyl-4-yl)butanoyl]amino}-5-chloro-2-methoxybenzoate 
• 1346763-38-9 trans-4-[{2-[({[4-({[tert-butyl(dimethyl)silyl]oxy}methyl)-2-chloro-5-methoxyphenyl]amino}carbonyl)oxy]ethyl}(methyl)amino]cyclohexylhydroxyl(di-2-thienyl)acetate 
• 1346763-36-7 tert-butyl[(5-chloro-4-isocyanato-2-methoxybenzyl)oxy]dimethylsilane 
• 1346763-13-0 N-[4-({[tert-butyl(dimethyl)silyl]oxy}methyl)-2-chloro-5-methoxyphenyl]acrylamide 
• 1254102-36-7 4-({[tert-butyl(dimethyl)silyl]oxy}methyl)-2-chloro-5-methoxyaniline 
• 1254102-35-6 (4-amino-5-chloro-2-methoxyphenyl)methanol 
• 1346763-43-6 trans-4-[[2-({[(2-chloro-4-formyl-5-methoxyphenyl)amino]carbonyl}oxy)ethyl](methyl)amino]cyclohexyl hydroxy(di-2-thienyl)acetate 
• 1346763-42-5 trans-4-[{2-[({[2-chloro-4-(hydroxymethyl)-5-methoxyphenyl]amino}carbonyl)oxy]ethyl}(methyl)amino]cyclohexyl hydroxy(di-2-thienyl)acetate 
• 1346763-18-5 trans-4-((3-(2-chloro-4-formyl-5-methoxyphenylamino)-3-oxopropyl)(methyl)amino)cyclohexyl hydroxy(di-2-thienyl)acetate 
• 1346763-16-3 trans-4-((3-(2-chloro-4-(hydroxymethyl)-5-methoxyphenylamino)-3-oxopropyl)(methyl)amino)cyclohexyl hydroxy(di-2-thienyl)acetate 
• 1346763-15-2 trans-4-((3-(4-((tert-butyl(dimethyl)silyloxy)methyl)-2-chloro-5-methoxyphenylamino)-3-oxopropyl)(methyl)amino)cyclohexyl hydroxy(di-2-thienyl)-acetate 

Relevant academic research and scientific papers

New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities

The present invention relates to novel compounds having β2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.

NEW CYCLOHEXYLAMINE DERIVATIVES HAVING β2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES

The present invention relates to novel compounds having β2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.

Drug evolution concept in drug design: 1. Hybridization method

A novel concept, "drug evolution", is proposed to develop chemical libraries that have a high probability of finding drugs or drug candidates. It converts biological evolution into chemical evolution. In this paper, we present "hybridization" drug evolution, which is the equivalent of sexual recombination of parental genomes in biological evolution. The hybridization essentially shuffles the building blocks of the parent drugs and ought to drug(s); no drug evolution can otherwise occur. We hybridized two drugs, benzocaine and metoclopramide and generated 16 molecules that include the parent drugs, four known drugs, and two molecules whose therapeutic activities are reported. The unusually high number of drugs and drug candidates in the library encourages high expectations of finding new drug(s) or drug candidate(s) within the remaining eight compounds. Interestingly, the therapeutic applications of the eight drugs or drug candidates in the library are fairly diverse as 38 therapeutic applications and 25 molecular targets are counted. Therefore, the library fits as a general chemical library for unspecified therapeutic activities. The hybridization of other two drugs, aspirin and cresotamide, is also described to demonstrate the generality of the method.